Boston Scientific Corporation (BSX) — closed signal from September 28, 2025
Partial Published before the outcome was known, scored automatically when the window closed on December 27, 2025.
Predicted vs. what happened
What happened
Reached 38% of the predicted growth at its peak, without hitting the target.
The thesis — published September 28, 2025
Boston Scientific looks ready for a rebound after heavy selling tied to U.S. questions about medical devices coming from Europe. Selling seems exhausted, while the company's long-term innovation story remains strong. The recent average price is drifting lower, so consider buying in small steps on dips, aiming for a move back toward typical levels over about three months as nerves fade and buyers come back.
Primary drivers
- The stock looks washed out, so a short-term bounce is more likely
- An industry investigation shook prices, not the company itself
- Respected brand and solid pipeline keep confidence and demand intact
- As worries fade, the price could return toward its usual trading range
How it played out
BSX: rebound started but target was not reached
Lyra published BSX at $98.18 on 2025-09-28 with an expected 20% move to $117.82 over the short term. The thesis pointed to exhausted selling after U.S. questions about European medical devices, a respected brand, a solid pipeline, and a return toward the usual trading range as worries faded.
Inside the window, the stock did rebound, but only partway. It peaked at $105.65 on 2025-11-13, a 7.6% gain, and stayed below the target. It never got there. By 2025-12-27, BSX ended at $96.06, below the publication price. The thesis partially played out, then faded.
What happened during the window
On 2025-10-22, Boston Scientific reported third-quarter results. Investors.com reported adjusted earnings of $0.75 per share on $5.07 billion in revenue, with organic sales up 15.3%. On the same date, MarketWatch reported that BSX closed at $103.85 after rising 3.95%. These were reported facts, not stated causes of the full-window outcome.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.